Ardelean, Gavril - Buicu, Florin (szerk.): Satu Mare. Studii şi comunicări. Seria ştiinţele naturale 8. (2007)

Medicină

Satu Mare - Studii şi Comunicări Seria Ştiinţele Naturii Voi. VIII (2007)

trial. Arch Dermatol 2006 Aug; 142(8): 1066-7

9. Green CA, Farr PM, Shuster S: Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol 1987 Feb; 116(2): 217-21

10. Groisser D, Bottone EJ, Lebwohl M: Association of Pityrosporum orbiculare (Malassezia furfur) with seborrheic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol 1989 May; 20(5 Pt 1): 770-3

11. Habif TP. Clinical dermatology: a color guide to diagnosis and therapy, 3d ed. St. Louis: Mosby, 1996:214.

12. Hay RJ, Graham-Brown RA. Dandruff and seborrhoeic dermatitis: causes and management. Clin Exp Dermatol 1997;22:3-6.

13. High WA, Pandya AG: Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol 2006 Jun; 54(6): 1083- 8

14. Janniger CK, Schwartz RA. Seborrheic dermatitis. Am Fam Physician 1995;52:149-55, 159-60 [published erratum appears in Am Fam Physician 1995^2:782],

15. Knaggs H, Bajor J, Becker W. The Sebumeter® and its use. Retinoids 1999; 15: 15-7.

16. Lévéque JL, Piérard-Franchimont C, de Rigai J, Saint-Léger D, Piérard GE. Effect of topical corticosteroids on the human sebum production assessed by two different methods. Arch Dermatol Res 1991;283:372-6.

17. Odom RB: Seborrheic dermatitis in AIDS. J Int Postgrad Med 1990; 2: 18-20.

18. Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhoea and acne. Dermatology 1998;196:140-7.

19. Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998;139:254-63.

20. Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebocontrolled trial. Br J Dermatol 1995; 132:441-5.

21. Piérard GE, Ries G, Cauwenbergh G. New insight in the topical management of excessive sebum flow at the skin surface. Dermatology 1998; 196:126-9.

22. Piérard GE. Relevance, comparison and validation of techniques. In: Serup J,Jemec GBE, eds. Handbook of non-invasive methods and the skin. CRC Press, Boca Raton. 1995: 9-14.

23. Piérard-Franchimont C, Goffin V, Visser JN, Jacoby H, Piérard GE. A double-blind controlled evaluation of the sebosuppressive activity of topical erythromycin-zinc complex. Eur J Clin Pharmacol 1995; 49: 57-60.

24. Schaub NA, Drewe J, Sponagel L, Gilli L, Courvoisier S, Gyr N, et al. Is there a relation between risk groups or initial CD4 T cell counts and prevalence of seborrheic dermatitis in HIV-infected patients? Dermatology 1999;198:126-9.

25. Schechtman RC, Midgley G, Hay RJ. HIV disease and Malassezia yeasts: a quantitative study of patients presenting with seborrhoeic dermatitis. Br J Dermatol 1995;133:694-8.

26. Schwartz RA, Janusz CA, Janniger CK: Seborrheic dermatitis: an overview. Am Fam Physician 2006 Jul 1; 74(1): 125-30

27. Siadat AH, Iraji F, Shahmoradi Z, et al: The efficacy of 1% metronidazole gel in facial seborrheic dermatitis: a double blind study. Indian J Dermatol Venereol Leprol 2006 Jul-Aug; 72(4): 266-9

28. Verschoore M, Poncet M, Krebs B, Ortonne JP. Circadian variations in the number of actively secreting sebaceous follicles and androgen circadian rhythms. Chronobiol Int 1993; 10: 349-59.

29. Zisova LG: Fluconazole and its place in the treatment of seborrheic dermatitisnew therapeutic possibilities. Folia Med (Plovdiv) 2006; 48(1): 39-45

30. Zouboulis CC, Xia L, Akamatsu H, Seitmann H, Fritsch M, Homemann S, et al. The human sebocyte culture model provides new insights into development and management of seborrhoea and acne. Dermatology 1998;196:21-31.

79